Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 5 of 5 entries
Sorted by: Best Match Show Resources per page
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants.

Neurology. Genetics

Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, Deming Y, Henson RL, Mikesell RJ, Piccio L, Llibre-Guerra JJ, Moulder KL, Fagan AM, Ances BM, Benzinger TLS, Xiong C, Holtzman DM, Morris JC.
PMID: 33884297
Neurol Genet. 2021 Mar 04;7(2):e571. doi: 10.1212/NXG.0000000000000571. eCollection 2021 Apr.

OBJECTIVE: To evaluate for racial differences in triggering receptor expressed on myeloid cells 2 (TREM2), a key immune mediator in Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2), and the frequency of associated genetic variants were compared in...

Cite
Schindler SE, Cruchaga C, Joseph A, et al. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurol Genet. 2021;7(2):e571doi: 10.1212/NXG.0000000000000571.
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L., Farias, F. H. G., Wilkins, C. H., Deming, Y., Henson, R. L., Mikesell, R. J., Piccio, L., Llibre-Guerra, J. J., Moulder, K. L., Fagan, A. M., Ances, B. M., Benzinger, T. L. S., Xiong, C., Holtzman, D. M., & Morris, J. C. (2021). African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology. Genetics, 7(2), e571. https://doi.org/10.1212/NXG.0000000000000571
Schindler, Suzanne E, et al. "African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants." Neurology. Genetics vol. 7,2 (2021): e571. doi: https://doi.org/10.1212/NXG.0000000000000571
Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, Deming Y, Henson RL, Mikesell RJ, Piccio L, Llibre-Guerra JJ, Moulder KL, Fagan AM, Ances BM, Benzinger TLS, Xiong C, Holtzman DM, Morris JC. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurol Genet. 2021 Mar 04;7(2):e571. doi: 10.1212/NXG.0000000000000571. eCollection 2021 Apr. PMID: 33884297; PMCID: PMC8054965.
Copy Download .nbib Format: NLM
Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25.

Neurobiology of aging

Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, Cruchaga C, Ladenson JH, Holtzman DM, Morris JC, Ances BM, Schindler SE.
PMID: 33765432
Neurobiol Aging. 2021 Jun;102:64-72. doi: 10.1016/j.neurobiolaging.2021.02.008. Epub 2021 Feb 11.

Cerebrospinal fluid (CSF) synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) are recently described biomarkers for pre- and postsynaptic integrity known to be elevated in symptomatic Alzheimer disease (AD). Their relationship with Apolipoprotein E (APOE) ε4 carrier status, the major...

Cite
Butt OH, Long JM, Henson RL, et al. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiol Aging. 2021;102:64-72doi: 10.1016/j.neurobiolaging.2021.02.008.
Butt, O. H., Long, J. M., Henson, R. L., Herries, E., Sutphen, C. L., Fagan, A. M., Cruchaga, C., Ladenson, J. H., Holtzman, D. M., Morris, J. C., Ances, B. M., Schindler, S. E. (2021). Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiology of aging, 10264-72. https://doi.org/10.1016/j.neurobiolaging.2021.02.008
Butt, Omar H, et al. "Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25." Neurobiology of aging vol. 102 (2021): 64-72. doi: https://doi.org/10.1016/j.neurobiolaging.2021.02.008
Butt OH, Long JM, Henson RL, Herries E, Sutphen CL, Fagan AM, Cruchaga C, Ladenson JH, Holtzman DM, Morris JC, Ances BM, Schindler SE. Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25. Neurobiol Aging. 2021 Jun;102:64-72. doi: 10.1016/j.neurobiolaging.2021.02.008. Epub 2021 Feb 11. PMID: 33765432.
Copy Download .nbib Format: NLM
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.

Neurology

Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C.
PMID: 34504028
Neurology. 2021 Nov 02;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 09.

BACKGROUND AND OBJECTIVES: To predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).METHODS: Brain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR)...

Cite
Schindler SE, Li Y, Buckles VD, et al. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. 2021;97(18):e1823-e1834doi: 10.1212/WNL.0000000000012775.
Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., Bateman, R. J., Morris, J. C., & Xiong, C. (2021). Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 97(18), e1823-e1834. https://doi.org/10.1212/WNL.0000000000012775
Schindler, Suzanne E, et al. "Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET." Neurology vol. 97,18 (2021): e1823-e1834. doi: https://doi.org/10.1212/WNL.0000000000012775
Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. 2021 Nov 02;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 09. PMID: 34504028; PMCID: PMC8610624.
Copy Download .nbib Format: NLM
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET.

Neurology

Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C.
PMID: 34504028
Neurology. 2021 Nov 02;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 09.

BACKGROUND AND OBJECTIVES: To predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).METHODS: Brain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR)...

Cite
Schindler SE, Li Y, Buckles VD, et al. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. 2021;97(18):e1823-e1834doi: 10.1212/WNL.0000000000012775.
Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., Bateman, R. J., Morris, J. C., & Xiong, C. (2021). Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 97(18), e1823-e1834. https://doi.org/10.1212/WNL.0000000000012775
Schindler, Suzanne E, et al. "Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET." Neurology vol. 97,18 (2021): e1823-e1834. doi: https://doi.org/10.1212/WNL.0000000000012775
Schindler SE, Li Y, Buckles VD, Gordon BA, Benzinger TLS, Wang G, Coble D, Klunk WE, Fagan AM, Holtzman DM, Bateman RJ, Morris JC, Xiong C. Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology. 2021 Nov 02;97(18):e1823-e1834. doi: 10.1212/WNL.0000000000012775. Epub 2021 Sep 09. PMID: 34504028; PMCID: PMC8610624.
Copy Download .nbib Format: NLM
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants.

Neurology. Genetics

Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, Deming Y, Henson RL, Mikesell RJ, Piccio L, Llibre-Guerra JJ, Moulder KL, Fagan AM, Ances BM, Benzinger TLS, Xiong C, Holtzman DM, Morris JC.
PMID: 33884297
Neurol Genet. 2021 Mar 04;7(2):e571. doi: 10.1212/NXG.0000000000000571. eCollection 2021 Apr.

OBJECTIVE: To evaluate for racial differences in triggering receptor expressed on myeloid cells 2 (TREM2), a key immune mediator in Alzheimer disease, the levels of CSF soluble TREM2 (sTREM2), and the frequency of associated genetic variants were compared in...

Cite
Schindler SE, Cruchaga C, Joseph A, et al. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurol Genet. 2021;7(2):e571doi: 10.1212/NXG.0000000000000571.
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L., Farias, F. H. G., Wilkins, C. H., Deming, Y., Henson, R. L., Mikesell, R. J., Piccio, L., Llibre-Guerra, J. J., Moulder, K. L., Fagan, A. M., Ances, B. M., Benzinger, T. L. S., Xiong, C., Holtzman, D. M., & Morris, J. C. (2021). African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology. Genetics, 7(2), e571. https://doi.org/10.1212/NXG.0000000000000571
Schindler, Suzanne E, et al. "African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants." Neurology. Genetics vol. 7,2 (2021): e571. doi: https://doi.org/10.1212/NXG.0000000000000571
Schindler SE, Cruchaga C, Joseph A, McCue L, Farias FHG, Wilkins CH, Deming Y, Henson RL, Mikesell RJ, Piccio L, Llibre-Guerra JJ, Moulder KL, Fagan AM, Ances BM, Benzinger TLS, Xiong C, Holtzman DM, Morris JC. African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurol Genet. 2021 Mar 04;7(2):e571. doi: 10.1212/NXG.0000000000000571. eCollection 2021 Apr. PMID: 33884297; PMCID: PMC8054965.
Copy Download .nbib Format: NLM
Showing 1 to 5 of 5 entries